Sales & Marketing News | pharmaphorum

News

J&J raises talc offer to $9bn with new insolvency bid

Johnson & Johnson has made an offer of nearly $9 billion to try to resolve tens of thousands of lawsuits it faces in the US that claim its talc products cause cancer.&

News

Okyo Pharma abandons UK listing in favour of Nasdaq

Okyo Pharma has decided to delist its shares from the London Stock Exchange and list them on the Nasdaq in New York, blaming “negligible” trading that doesn’t justify the

News

FDA clears Keytruda/Padcev regimen for bladder cancer

The combination of Merck & Co’s checkpoint inhibitor Keytruda and Seagen/Astellas’ antibody-drug conjugate Padcev has been approved by the FDA as an alternative to che

News

J&J’s bankruptcy bid to resolve talc claims blocked

Johnson & Johnson’s attempt to draw a line under the ongoing litigation it faces over allegations that its talc products cause cancer has been blocked by an appeals co

News

US government says SCOTUS should hear ‘skinny label’ case

The White House has told the US Supreme Court that it should hear a hotly-contested lawsuit between Teva and GSK that could have ramifications on the ability of generic dr

News

GSK licenses out new HIV PrEP drug in poorer nations

GSK’s majority-owned HIV unit ViiV has agreed licensing deals with a trio of generic manufacturers to make its recently-approved long-acting drug for pre-exposure prophyla

J&J raises talc offer to $9bn with new insolvency bid

Okyo Pharma abandons UK listing in favour of Nasdaq

FDA clears Keytruda/Padcev regimen for bladder cancer

J&J’s bankruptcy bid to resolve talc claims blocked

US government says SCOTUS should hear ‘skinny label’ case

GSK licenses out new HIV PrEP drug in poorer nations

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks